Targeted Protein Degradation
Targeted Protein Degradation (TPD) drugs are of a new modality that can degrade and remove target proteins using the Ubiquitin-Proteasome system (UPS), which is one of the natural protein degradation systems in cells. The UPS labels the protein to be degraded using ubiquitin through a series of actions of E1, E2, and E3. In this process, E3 ligase plays a very crucial role in target protein selection and recognition. TPD using UPS can target pathogenic proteins that could not be targeted with conventional small molecule inhibitors. It is a superior therapeutic modality compared to existing small molecule inhibitors in terms of efficacy and target selectivity.
Since its establishment in 2017, Pin has been focusing on the development of TPD technology and is developing two types of drugs: PROTAC (PROteolysis-TArgeting Chimera) and Molecular Glue Degrader. PROTAC and Molecular Glue Degrader act by similar mechanisms to degrade target proteins but have different properties in terms of compound structure, drug properties, and ease of selection of target proteins. Pin aims to have platform technologies for both types of TPD, and through this, purses to become a world-class biotech leading the TPD field.